{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:18:42Z","timestamp":1792707522578,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2026.36756","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:30:24Z","timestamp":1790695824000},"page":"e2636756","source":"Crossref","is-referenced-by-count":1,"title":["Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT"],"prefix":"10.1001","volume":"9","author":[{"given":"Otto","family":"Simonsson","sequence":"first","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Black","sequence":"additional","affiliation":[{"name":"Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karilynn M.","family":"Rockhill","sequence":"additional","affiliation":[{"name":"Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Monte","sequence":"additional","affiliation":[{"name":"Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"10","key":"zld260222r3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"zld260222r4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41591-023-02705-w","article-title":"Magnesium-ibogaine therapy in veterans with traumatic brain injuries.","volume":"30","author":"Cherian","year":"2024","journal-title":"Nat Med"},{"key":"zld260222r5","doi-asserted-by":"publisher","DOI":"10.1111\/add.70260","article-title":"5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: an open-label, phase 2, proof-of-concept, clinical trial.","author":"Marsden","year":"2025","journal-title":"Addiction"},{"issue":"11","key":"zld260222r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3630","article-title":"Psychedelic and MDMA-related adverse effects\u2014a call for action.","volume":"5","author":"Simonsson","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"1","key":"zld260222r7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US.","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"zld260222r8","doi-asserted-by":"publisher","DOI":"10.2196\/86059","article-title":"Fusing specialized surveys of rare populations to larger surveys for generalized inference: cross-sectional survey study.","volume":"28","author":"Rockhill","year":"2026","journal-title":"J Med Internet Res"},{"key":"zld260222r9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jad.2024.08.091","article-title":"Validation of the Swiss Psychedelic Side Effects Inventory: standardized assessment of adverse effects in studies of psychedelics and MDMA.","volume":"365","author":"Calder","year":"2024","journal-title":"J Affect Disord"},{"issue":"1","key":"zld260222r10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/add.15448","article-title":"Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.","volume":"117","author":"Knuijver","year":"2022","journal-title":"Addiction"},{"key":"zld260222r1","unstructured":"Compass Pathways. Compass Pathways announces six-month data from second phase 3 trial confirming rapid and durable profile. July 7, 2026. Accessed July 12, 2026. https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2026\/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile\/default.aspx"},{"key":"zld260222r2","unstructured":"Definium Therapeutics. Definium Therapeutics announces positive topline results from phase 3 Emerge study of DT120 orally disintegrating tablet (ODT) in major depressive disorder. June 22, 2026. Accessed July 12, 2026. https:\/\/ir.definiumtx.com\/news-events\/press-releases\/detail\/232\/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-study-of-dt120-orally-disintegrating-tablet-odt-in-major-depressive-disorder"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854616\/simonsson_2026_ld_260222_1790096172.73349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:30:25Z","timestamp":1790695825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.36756","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}